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ABSTRACT 
 A Stability Indicating Ultra-Performance Liquid Chromatography method was developed and 
validated for quantification of Axitinib in tablets. The chromatographic separation was done 
in an isocratic mode using the STD RP-18 Endcapped (50mm × 4.6mm, 2µ particle size) 
column. The mobile phase 0.1% OPA and acetonitrile 55:45 (%v/v) at the flow rate of 
0.2mL/min and at ambient temperature was used. The wavelength used for detection was 
249nm. The retention time for Axitinib was found to 1.03min. Axitinib was linear in the 
concentration range of 12.5µg/mL to 75µg/mL respectively. The developed method was 
validated and found to be accurate, specific and robust. The drug was subjected to the stressed 
conditions like acidic, basic, oxidative, photolytic, thermal and neutral conditions. The 
degradation results are found satisfactory. This method can be applied for the estimation of 
Axitinib in pharmaceutical dosage forms. 
  
Introduction 
 
Axitinib (Fig.1), chemically designated as N-Methyl-2-[[3-
[(E)-2-pyridin-2-ylethenyl]-1H-indazol-6-
yl]sulfanyl]benzamide, is a white to light yellow powder, 
slightly soluble in methanol, ethanol and water and has a pKa 
of 4.8. It is used in the treatment of advanced renal cell 
Carcinoma by acting as tyrosine kinase receptors VEGFR-1 
(vascular endothelial growth factor receptor), VEGFR-2, and 
VEGFR-3 blocker [1-3]. According to the literature survey, 
very few methods were developed using HPLC [4-6]only. As 
no UPLC method was developed, the proposed method aimed 
to develop and validate a stability indicating method for the 
estimation of Axitinib in pharmaceutical dosage form using 
UPLC.   
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Fig.1: Chemical structure of Axitinib 
Material and Methods 
 
Reagents and Chemicals 
 Axitinib standard drug was supplied as gift sample by 
spectrum labs, Hyderabad (India). The Axitinib Tablets 
(Inlyta) were purchased from local pharmacy. All the solvents 
used were of HPLC grade and purchased from Merck, 
Mumbai, India. All the chemicals used for developing method 
were of AR grade and purchased from sigma Aldrich. 
  
Instruments and Chromatographic conditions 
 Water ACQUITY UPLC system equipped with Binary 
solvent manager, a sample manager with STD RP-18 End 
capped (50mm × 4.6mm, 2µ particle size) column maintained 
at room temperature, a solvents tray and UV detector was used 
for the estimation of Axitinib in pharmaceutical dosage form.  
All the parameters of UPLC were controlled by Empower 
software. Other instruments used were electronic balance, 
digital pH meter and Ultrasonic bathsonicator. The mobile 
phase composition 0.1% Orthophosphoric acid and acetonitrile 
(55:45%v/v) was used on isocratic mode at a flow rate of 
0.2mL/min. The detection wavelength used was 249nm.  
 
Preparation of standard solution and sample solution 
5mg of Axitinib working standard was accurately weighed and 
transferred into a 10mL volumetric flask. 7mL of diluent was 
added, sonicated to dissolve and make up to final volume with 
diluent. From the above stock solution, 1mL was pipetted into 
a 10mL volumetric flask and the volume was made up to mark 
with diluent. 
20 Tablets (Inlyta) were weighed accurately and the average 
weight was calculated. The tablets were crushed and fine 
powder was collected. An amount equivalent to 5mg of 
Axitinib was weighed and transferred into 10mL volumetric 
flask. 7mL of diluent was added and sonicated for 30min with 
intermediate shaking. Volume was made up with diluent. The 
above solution was filtered using UPLC filters. 1mL of the 
above solution was pipette into 10mL volumetric flask and 
made up with diluent. 
Method validation [7] 
 
System suitability 
Inject standard solution into the chromatographic system and 
calculate the parameters such as % relative standard deviation 
(RSD), tailing factor and plate count. 
 
Linearity 
Serial dilutions of standard Axitinib in the concentration range 
of 12.5µg/mL and 75µg/mL were prepared and injected into 
the UPLC. A linearity graph was plotted between 
concentration and peak areas.  
 
Accuracy 
 The solutions were prepared in three different concentration 
levels of 50%, 100% and 150%, injected into UPLC and % 
recoveries were calculated.  
 
Precision 
 The precision of the method was determined by Intra and 
Inter-day precision studies. The standard solution was injected 
six times on the same day (intra-day) as well as on different 
day (inter-day) and the % RSD was calculated. 
 
Specificity 
The specificity of the method was determined by injecting the 
placebo solution and comparing with standard solution for the 
interference with Axitinib peak.  
 
Limit of Detection (LOD) and Limit of Quantitation 
(LOQ) 
 LOD and LOQ are determined by standard deviation (SD) 
and slope of the calibration curve. The limiting values are 
calculated as per the following equations: LOD = (3.3 × SD)/ 
Slope and LOQ = (10 × SD)/ Slope. 
 
Robustness 
 Robustness of the method was determined by varying the 
optimum chromatographic conditions such as mobile phase 
ratio (±10%), flow rate (±0.1mL/min) and column oven 
temperature (±5ºC). The system suitability parameters were 
calculated and recorded.   
 
Forced degradation studies 
 The drug solution was subjected to the various stress 
conditions such as acidic (2N Hydrochloric acid, 60 ºC for 30 
min), basic (2N sodium hydroxide, 60 ºC for 30 mins), 
oxidative (20% hydrogen peroxide, 60 ºC for 30 min), neutral 
(refluxingthedruginwaterfor6hrsatatemperature of 60ºC), 
photolytic (exposing the drug solution to UV light by keeping 
the beaker in UV Chamber for 7 days or 200Watt hours/m
2 
in 
photo stability chamber) and thermal ( drug solution was 
placed in an oven at 105ºC for 6 hours) conditions.  
 
Results and Discussion 
The main aim of the study was to develop a stability indicating 
UPLC method for the estimation of Crizotinib in capsule 
dosage form and to validate the method. Initially various 
mobile phase compositions were tried to elute the drug. 
Mobile phase ratio and flow rate were selected based on peak 
parameters and retention time. Standard solution of 50µg/mL 
was prepared and scanned in the range of 200 – 400nm for 
detecting the maximum absorption wavelength and it was 
found to be 249nm (Fig.2). 
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Fig.2: UV spectrum of Axitinib 
After considering the entire system suitability parameters 
mobile phase 0.1% OPA and acetonitrile (55:45%v/v) run in 
isocratic mode and flow rate 0.2ml/min was selected. The 
retention time of Axitinib was found to be 1.028 min. The 
system suitability parameters are calculated from standard 
chromatogram (Table No. 1 and Fig.3) 
 
Fig.3: Standard chromatogram of Axitinib 
For the estimation of linearity of method, concentrations 
ranging from 12.5µg/mL to 75µg/mL were prepared and a 
linearity graph (Fig.4) was plotted using concentration against 
peak area. The regression equation was found to be y = 
8007.8x + 5131.2, with a correlation coefficient of 0.9997, 
indicating that a good linearity was observed
. 
 
Fig.4: Linearity plot of Axitinib 
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The % recovery of Axitinib was found to be 99.49% - 99.80% 
and % RSD was found to be 0.3. As the results were found to 
be within the limits, indicates that the method was accurate 
and precise. The LOD and the LOQ for Axitinib were found to 
be 0.26µg/mL and 0.80µg/mL respectively. The method was 
found to be rugged, robust and stable up to 24hrs. The method 
was found to be specific, as there is no interference of placebo 
peaks with the retention time of Axitinib as shown in Fig.5. 
 
Fig.5: Placebo chromatogram 
 
Table No. 1 System suitability and validation parameter results 
 
 
The stability of an analytical method was determined by 
forced degradation studies, in which the stability of the 
method was carried out by performing Acid stress study, Base  
 
 
stress study, Peroxide stress study, Water stress study, UV 
light exposurestudy and Dry heat stress study.  The net 
degradation was found to be within the limits. The results and 
chromatograms were summarized in Table No. 2 and Fig.6.  
Table No. 2 Result of Forced degradation studies 
 
S.No. Stress condition % Assay  % area of degradation peak 
1 2N HCL for 30mins at 60°C 95.94 2.27 
2 2N NaOH for 30mins  at 60°C 97.94 0.17 
3 20% H2O2 for 30mins at 60
0
C 98.10 - 
4 Water for 6hrs at60
0
C 99.36 - 
5 UV light 200wts/hr or 7 days 99.61 - 
6 105
0
C for 6hrs 99.48 - 
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Fig.6a:Acid degradation chromatogram                 Fig.6b:Base degradation chromatogram 
 
Fig.6c:  Peroxide degradation chromatogram     Fig.6d: Water stress study chromatogram 
 
Fig.6e: Photo stability degradation chromatogram   Fig.6f: Dry heat study chromatogram 
 
Conclusion 
 
A specific, accurate stability indicating method was developed 
for the estimation of Axitinib in pharmaceutical dosage form 
using UPLC. The method was validated by using various 
validation parameters and the method was found to be linear, 
precise, accurate, specific and robust. From the degradation 
studies conducted it is concluded that Axitinib was more 
stable at more concentrations of acid, base, peroxide, thermal, 
UV and water stress study conditions. The run time was 2min 
which enables rapid quantitation of many samples in routine 
and quality control analysis of capsule formulations. 
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